ImmunityBio, Inc. Price & Performance (IBRX)

ImmunityBio reported a 97% increase in ANKTIVA sales in February 2025 compared to December 2024, driven by the permanent J-code issued in January. The company also announced FDA authorization for recombinant BCG distribution to address shortages, targeting 45,000 vials for U.S. distribution this year.12

ImmunityBio has started distributing recombinant BCG to address the U.S. bladder cancer treatment shortage. With 60 sites activated, the company aims to prevent delays in ANKTIVA treatments. This effort follows FDA authorization, marking a key milestone in alleviating supply constraints for critical therapies.34

H.C. Wainwright reaffirmed an $8 price target for ImmunityBio stock, citing FDA approvals and sales growth. However, analysts highlighted challenges, including cash burn and competition. Despite these risks, the stock has gained 19.5% year-to-date, reflecting confidence in its therapeutic advancements and market strategy.56